<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01779570</url>
  </required_header>
  <id_info>
    <org_study_id>RGC CUHK468112</org_study_id>
    <nct_id>NCT01779570</nct_id>
  </id_info>
  <brief_title>Anti-inflammatory Effects of Macrolide Treatment in Influenza Lower Respiratory Tract Infections</brief_title>
  <official_title>Anti-inflammatory Effects of Macrolide Treatment in Influenza Lower Respiratory Tract Infections</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chinese University of Hong Kong</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chinese University of Hong Kong</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Influenza lower respiratory tract infection (LRTI) is a major cause of morbidity and
      mortality worldwide. While viral replication can be suppressed by antiviral treatment,
      excessive inflammatory responses, which are increasingly recognized to contribute to severe
      influenza complications, remain unopposed. Macrolides have been used widely to treat
      community-acquired pneumonia, and shown to exert anti-inflammatory effects in other
      respiratory diseases, providing clinical benefits. In this randomized, open-label,
      multicenter study, we aim to investigate the anti-inflammatory effects of macrolide treatment
      in influenza LRTI. Its impacts on the cytokine response, viral clearance, symptoms and
      disease resolution will be studied. Such results may lead to the development of new
      therapeutic approaches against severe influenza infection, and provide better insights into
      disease pathogenesis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Objectives: (1) We aim to investigate the anti-inflammatory effects of macrolide treatment in
      patients with influenza LRTI and the impact on viral clearance. (2) To investigate the impact
      of macrolide treatment on influenza symptom and disease resolution.

      Design: A randomized, open-label, multicenter study.

      Settings: Acute medical facilities in 3 general public hospitals in Hong Kong.

      Subjects, Sampling and Intervention: Adult (&gt;/=18 years) patients hospitalized for
      virologically confirmed influenza LRTI who fulfill the inclusion/exclusion criteria will be
      randomized to receive (1) azithromycin 500 mg p.o. for 5 days (in addition to antiviral, as
      part of usual care), or (2) no azithromycin (ie, antiviral alone, part of usual care) after
      informed consent. Serial blood samples will be collected for cytokine/inflammatory response
      assays. Serial nasopharyngeal swabs will be collected to assess for viral clearance.
      Symptoms, clinical progress, radiography and adverse events will be monitored.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2013</start_date>
  <completion_date type="Actual">April 2016</completion_date>
  <primary_completion_date type="Actual">April 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>cytokine and inflammatory responses</measure>
    <time_frame>within 10 days post-intervention</time_frame>
    <description>Serial measurements of selected cytokines/chemokines (e.g. interleukin-6, CXCL8) and proinflammatory molecules (e.g. DAMPs)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>viral clearance</measure>
    <time_frame>within 10 days post-intervention</time_frame>
    <description>Viral RNA and culture negativity in serially collected respiratory tract specimens</description>
  </secondary_outcome>
  <other_outcome>
    <measure>time to recovery</measure>
    <time_frame>within 10 days post-intervention</time_frame>
    <description>e.g. time to symptom resolution, time to hospital discharge, etc</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">68</enrollment>
  <condition>Influenza</condition>
  <condition>Lower Respiratory Tract Infection</condition>
  <arm_group>
    <arm_group_label>Macrolide treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Azithromycin 500 mg daily for 5 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No macrolide treatment</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>No azithromycin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Macrolide treatment</intervention_name>
    <arm_group_label>Macrolide treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. established influenza A or B infection by virologic tests

          2. age &gt;/=18 years

          3. present within 4 days from illness onset

          4. clinical evidence of LRTI and require hospital care

          5. require antiviral (oseltamivir) treatment

          6. able to provide written, informed consent.

        Exclusion Criteria:

          1. patients on immunosuppressants

          2. pregnant or lactating woman

          3. known hepatic failure, end-stage renal failure, cardiac arrhythmia (e.g. prolonged
             corrected QT interval &gt;450 msec)

          4. known contraindications to azithromycin (e.g. allergic reaction)

          5. lack of consent for study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nelson LS Lee, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chinese University of Hong Kong</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Prince of Wales Hospital</name>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Princess Margaret Hospital</name>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Hong Kong</country>
  </location_countries>
  <link>
    <url>http://www.mect.cuhk.edu.hk/specialties/infectiousdiseases.html</url>
    <description>Division of Infectious Diseases, Department of Medicine and Therapeutics, The Chinese University of Hong Kong</description>
  </link>
  <reference>
    <citation>Chan PK, Chan MC, Cheung JL, Lee N, Leung TF, Yeung AC, Wong MC, Ngai KL, Nelson EA, Hui DS. Influenza B lineage circulation and hospitalization rates in a subtropical city, Hong Kong, 2000-2010. Clin Infect Dis. 2013 Mar;56(5):677-84. doi: 10.1093/cid/cis885. Epub 2012 Oct 16.</citation>
    <PMID>23074315</PMID>
  </reference>
  <reference>
    <citation>Chan PK, Lee N, Zaman M, Adisasmito W, Coker R, Hanshaoworakul W, Gasimov V, Oner AF, Dogan N, Tsang O, Phommasack B, Touch S, Bamgboye E, Swenson A, Toovey S, Dreyer NA. Determinants of antiviral effectiveness in influenza virus A subtype H5N1. J Infect Dis. 2012 Nov;206(9):1359-66. doi: 10.1093/infdis/jis509. Epub 2012 Aug 20.</citation>
    <PMID>22927451</PMID>
  </reference>
  <reference>
    <citation>Lee N, Ison MG. Diagnosis, management and outcomes of adults hospitalized with influenza. Antivir Ther. 2012;17(1 Pt B):143-57. doi: 10.3851/IMP2059. Epub 2012 Feb 3. Review.</citation>
    <PMID>22311561</PMID>
  </reference>
  <reference>
    <citation>Lee N, Wong CK, Chan PK, Chan MC, Wong RY, Lun SW, Ngai KL, Lui GC, Wong BC, Lee SK, Choi KW, Hui DS. Cytokine response patterns in severe pandemic 2009 H1N1 and seasonal influenza among hospitalized adults. PLoS One. 2011;6(10):e26050. doi: 10.1371/journal.pone.0026050. Epub 2011 Oct 13.</citation>
    <PMID>22022504</PMID>
  </reference>
  <reference>
    <citation>Lee N, Chan PK, Lui GC, Wong BC, Sin WW, Choi KW, Wong RY, Lee EL, Yeung AC, Ngai KL, Chan MC, Lai RW, Yu AW, Hui DS. Complications and outcomes of pandemic 2009 Influenza A (H1N1) virus infection in hospitalized adults: how do they differ from those in seasonal influenza? J Infect Dis. 2011 Jun 15;203(12):1739-47. doi: 10.1093/infdis/jir187.</citation>
    <PMID>21606532</PMID>
  </reference>
  <reference>
    <citation>Lee N, Chan PK, Wong CK, Wong KT, Choi KW, Joynt GM, Lam P, Chan MC, Wong BC, Lui GC, Sin WW, Wong RY, Lam WY, Yeung AC, Leung TF, So HY, Yu AW, Sung JJ, Hui DS. Viral clearance and inflammatory response patterns in adults hospitalized for pandemic 2009 influenza A(H1N1) virus pneumonia. Antivir Ther. 2011;16(2):237-47. doi: 10.3851/IMP1722.</citation>
    <PMID>21447873</PMID>
  </reference>
  <reference>
    <citation>Lee N, Choi KW, Chan PK, Hui DS, Lui GC, Wong BC, Wong RY, Sin WY, Hui WM, Ngai KL, Cockram CS, Lai RW, Sung JJ. Outcomes of adults hospitalised with severe influenza. Thorax. 2010 Jun;65(6):510-5. doi: 10.1136/thx.2009.130799.</citation>
    <PMID>20522848</PMID>
  </reference>
  <reference>
    <citation>Hui DS, Lee N, Chan PK. Clinical management of pandemic 2009 influenza A(H1N1) infection. Chest. 2010 Apr;137(4):916-25. doi: 10.1378/chest.09-2344. Epub 2009 Dec 18.</citation>
    <PMID>20022969</PMID>
  </reference>
  <reference>
    <citation>Lee N, Chan PK, Hui DS, Rainer TH, Wong E, Choi KW, Lui GC, Wong BC, Wong RY, Lam WY, Chu IM, Lai RW, Cockram CS, Sung JJ. Viral loads and duration of viral shedding in adult patients hospitalized with influenza. J Infect Dis. 2009 Aug 15;200(4):492-500. doi: 10.1086/600383.</citation>
    <PMID>19591575</PMID>
  </reference>
  <reference>
    <citation>Lee N, Wong CK, Chan PK, Lun SW, Lui G, Wong B, Hui DS, Lam CW, Cockram CS, Choi KW, Yeung AC, Tang JW, Sung JJ. Hypercytokinemia and hyperactivation of phospho-p38 mitogen-activated protein kinase in severe human influenza A virus infection. Clin Infect Dis. 2007 Sep 15;45(6):723-31. Epub 2007 Aug 8.</citation>
    <PMID>17712756</PMID>
  </reference>
  <reference>
    <citation>Lee N, Chan PK, Choi KW, Lui G, Wong B, Cockram CS, Hui DS, Lai R, Tang JW, Sung JJ. Factors associated with early hospital discharge of adult influenza patients. Antivir Ther. 2007;12(4):501-8.</citation>
    <PMID>17668558</PMID>
  </reference>
  <verification_date>July 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 29, 2013</study_first_submitted>
  <study_first_submitted_qc>January 29, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 30, 2013</study_first_posted>
  <last_update_submitted>July 25, 2016</last_update_submitted>
  <last_update_submitted_qc>July 25, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 27, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chinese University of Hong Kong</investigator_affiliation>
    <investigator_full_name>Nelson Lee</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Influenza</keyword>
  <keyword>Macrolide</keyword>
  <keyword>Anti-inflammatory</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Influenza, Human</mesh_term>
    <mesh_term>Respiratory Tract Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anti-Inflammatory Agents</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

